# Bexarotene in Treating Patients With Metastatic Breast Cancer

> **NCT00003752** · PHASE2 · COMPLETED · sponsor: **Ligand Pharmaceuticals** · enrollment: 180 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** bexarotene

## Key facts

- **NCT ID:** NCT00003752
- **Lead sponsor:** Ligand Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-10
- **Primary completion:** —
- **Final completion:** 2003-03
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2013-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003752, "Bexarotene in Treating Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00003752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*